Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial.
- Leleu, Xavier
- Fouquet, Guillemette
- Richez, Valentine
- Guidez, Stéphanie
- Duhamel, Alain
- Machuron, François
- Karlin, Lionel
- Kolb, Brigitte
- Tiab, Mourad
- Araujo, Carla
- Meuleman, Nathalie
- Malfuson, Jean Valère
- Bourquard, Pascal
- Lenain, Pascal
- Roussel, Murielle
- Jaccard, Arnaud
- Pétillon, Marie-Odile
- Belhadj-Merzoug, Karim
- Lepeu, Gérard
- Chrétien, Marie-Lorraine
- Fontan, Jean
- Rodon, Philippe
- Schmitt, Anna
- Offner, Fritz
- Voillat, Laurent
- Cereja, Sophie
- Kuhnowski, Frédérique
- Rigaudeau, Sophie
- Decaux, Olivier
- Humbrecht-Kraut, Catherine
- Frayfer, Jamile
- Fitoussi, Olivier
- Roos-Weil, Damien
- Eisenmann, Jean Claude
- Dorvaux, Véronique
- Voog, Eric G
- Attal, Michel
- Moreau, Philippe
- Avet-Loiseau, Herve
- Hulin, Cyrille
- Facon, Thierry
Publication date
July 2019
DOI Publisher
American Association for Cancer Research (AACR)Abstract
Carfilzomib is a novel generation proteasome inhibitor. The Carmysap trial demonstrated that twice-weekly KMP (carfilzomib, melphalan, prednisone) might challenge the MPV (melphalan, prednisone, bortezomib) standard. We sought to study KMP weekly, allowing to increase carfilzomib's dose with maintained efficacy and improved safety profile.info:eu-repo/semantics/publishe
Add to ORKG